Meeting
2023 ASCO Annual Meeting
Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer.
Authors
Kelvin K H Bao
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong
Kelvin K H Bao , Jeffrey CH Chan , Leone Sutanto , Jocelyn G Chan , Ka Man Cheung , Harry HY Yiu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1043)
DOI
10.1200/JCO.2023.41.16_suppl.1043
Abstract #
1043
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).
First Author: Kazutaka Narui
Poster
2023 ASCO Breakthrough
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase Ib/II study.
First Author: Xiaojia Wang
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
Poster
2023 ASCO Annual Meeting
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.
First Author: Xiaojia Wang